Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

P4099900

Pyridostigmine bromide

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

3-(Dimethylaminocarbonyloxy)-1-methylpyridinium bromide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C9H13BrN2O2
Número de CAS:
101-26-8
Peso molecular:
261.12
Número MDL:
MFCD00079283
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329820197
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

pyridostigmine

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

[Br-].CN(C)C(=O)Oc1ccc[n+](C)c1

InChI

1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1

Clave InChI

VNYBTNPBYXSMOO-UHFFFAOYSA-M

Información sobre el gen

human ... ACHE(43)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Pyridostigmine bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Acetylcholinesterase inhibitor.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1586009

Pyridostigmine bromide, United States Pharmacopeia (USP) Reference Standard

P4099910

Pyridostigmine impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001486

Pyridostigmine impurity B, European Pharmacopoeia (EP) Reference Standard

1586020

Pyridostigmine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1586031

Pyridostigmine Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP1033

Pyridostigmine bromide, British Pharmacopoeia (BP) Reference Standard

PHR3120

Pyridostigmine Bromide, pharmaceutical secondary standard, certified reference material

Pictogramas

Skull and crossbones
GHS06

Palabra de señalización

Danger

Frases de peligro

H300 + H310 + H330,H317

Clasificaciones de peligro

Acute Tox. 1 Inhalation - Acute Tox. 2 Dermal - Acute Tox. 2 Oral - Skin Sens. 1

Código de clase de almacenamiento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

João Paulo J Sabino et al.
Autonomic neuroscience : basic & clinical, 173(1-2), 58-64 (2012-12-12)
Sympathetic hyperactivity and its outcome in heart failure have been thoroughly investigated to determine the focus of pharmacologic approaches targeting the sympathetic nervous system in the treatment of this pathophysiological condition. On the other hand, therapeutic approaches aiming to protect
Adil E Bharucha et al.
Gut, 62(5), 708-715 (2012-06-09)
Chronic constipation in diabetes mellitus is associated with colonic motor dysfunction and is managed with laxatives. Cholinesterase inhibitors increase colonic motility. This study evaluated the effects of a cholinesterase inhibitor on gastrointestinal and colonic transit and bowel function in diabetic
Renske I Wadman et al.
Neurology, 79(20), 2050-2055 (2012-11-02)
Spinal muscular atrophy (SMA) is pathologically characterized by degeneration of anterior horn cells. Recent observations in animal models of SMA and muscle tissue from patients with SMA suggest additional abnormalities in the development and maturation of the neuromuscular junction. We
Renata M Lataro et al.
American journal of physiology. Regulatory, integrative and comparative physiology, 305(8), R908-R916 (2013-08-21)
Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart. Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution. The parasympathetic neurotransmission can be improved
H Zach et al.
European journal of neurology, 20(4), 708-713 (2013-01-03)
Several small retrospective studies have observed that patients with a purely ocular manifestation of myasthenia gravis (MG) are significantly less likely to convert to a generalized disease when treated early on with corticosteroids. However, given the limited number of reported
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico